Celera Corp. will settle four shareholder lawsuits filed after Quest Diagnostics Inc. said it would buy the Alameda medical test developer for $344 million.
Meanwhile, Celera and Quest (NYSE: DGX) agreed to lower the deal’s termination fee to $15.6 million from $23.45 million, and Quest said it will extend its $8 per share offer until 5 p.m. (Eastern time) on May 2.
No comments:
Post a Comment